Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Iodixanol
Drug ID BADD_D01178
Description Iodixanol is a nonionic hydrophilic compound commonly used as a contrast agent during coronary angiography, particularly in individuals with renal dysfunction, as it is believed to be less toxic to the kidneys than most other intravascular contrast agents.
Indications and Usage Iodixanol is a contrast agent during coronary angiography.
Marketing Status approved
ATC Code V08AB09
DrugBank ID DB01249
KEGG ID D01474
MeSH ID C044834
PubChem ID 3724
TTD Drug ID D0Y4YG
NDC Product Code 71806-222; 65219-381; 0407-2223; 65219-383; 0407-2222; 57884-0029
UNII HW8W27HTXX
Synonyms iodixanol | Visipaque | Visipaque Unique Softpac | iodixanol-320 | contrast media 2-5410-3
Chemical Information
Molecular Formula C35H44I6N6O15
CAS Registry Number 92339-11-2
SMILES CC(=O)N(CC(CN(C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I)C(=O)C)O)C2=C(C(= C(C(=C2I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pulmonary embolism24.01.06.001; 22.06.02.001--Not Available
Pulmonary oedema22.01.03.003; 02.05.02.003--
Pyrexia08.05.02.0030.092474%
Rash23.03.13.0010.662968%Not Available
Rash erythematous23.03.13.0290.039124%Not Available
Rash macular23.03.13.0030.007113%Not Available
Rash maculo-papular23.03.13.0040.028454%
Rash morbilliform23.03.13.0050.007113%Not Available
Rash papular23.03.13.0170.010670%Not Available
Rash pruritic23.03.13.0300.092474%Not Available
Rash vesicular23.03.13.0090.007113%Not Available
Renal failure20.01.03.005--Not Available
Renal tubular necrosis20.01.07.0030.029876%Not Available
Respiratory arrest22.02.01.0090.028454%Not Available
Respiratory depression22.02.01.010; 17.02.05.0470.007113%Not Available
Respiratory distress22.02.01.0120.021340%Not Available
Respiratory failure22.02.06.002; 14.01.04.0030.024897%
Restlessness19.11.02.002; 17.02.05.0210.014227%
Retching07.01.07.0020.021340%Not Available
Rhabdomyolysis15.05.05.0020.010670%
Rhinitis22.07.03.006; 11.01.13.004--
Salivary hypersecretion07.06.01.009--Not Available
Seizure17.12.03.0010.056907%
Sense of oppression08.01.09.0200.007113%Not Available
Sensory disturbance17.02.07.006--Not Available
Shock24.06.02.0020.064020%Not Available
Sinus bradycardia02.03.03.009--
Sinus tachycardia02.03.03.0100.010670%
Sinusitis22.07.03.007; 11.01.13.005--
Skin exfoliation23.03.07.0030.024897%Not Available
The 7th Page    First    Pre   7 8 9 10    Next   Last    Total 10 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene